Tumour biology: herceptin acts as an anti-angiogenic cocktail.
about
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptorsIs NF-kappaB a good target for cancer therapy? Hopes and pitfallsAutocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosisThe role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerTyrosine kinase - Role and significance in Cancer.Developmental and pathological angiogenesis in the central nervous systemTrastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitorsUnraveling the microenvironmental influences on the normal mammary gland and breast cancerModulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancerAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells.NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Angiostatin up-regulation in gastric cancer cell SGC7901 inhibits tumorigenesis in nude mice.Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancerTrends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.Measuring Vascular Permeability In VivoThe thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.Trastuzumab emtansine: mechanisms of action and drug resistanceBrain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors.Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical modelsImaging angiogenesis and the microenvironment.Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumabIn vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.The role of mechanical forces in tumor growth and therapyOptimizing the management of HER2-positive early breast cancer: the clinical reality.The role of HER2 in cancer therapy and targeted drug deliveryBradykinin decreases podocyte permeability through ADAM17-dependent epidermal growth factor receptor activation and zonula occludens-1 rearrangementNanomedicine: towards development of patient-friendly drug-delivery systems for oncological applicationsTargeting HER2 in breast cancer: overview of long-term experienceOxidative aliphatic C-H fluorination with fluoride ion catalyzed by a manganese porphyrin.Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistanceThe epidermal growth factor receptor family in breast cancer.
P2860
Q24554356-E1CCD181-F39F-4540-BE21-CE27372F352AQ24570128-F86A7651-7561-4FCA-8A75-0B0FE90F4458Q24609324-53907E35-5182-4124-90D7-93400C9BEB12Q24656159-C16A6336-8EE6-46E3-9C0B-0BDE2523FF9EQ24791430-9D3D5B1E-FA81-43E1-A368-8CD3B482F37AQ27023250-37D7B0C2-103E-4B99-A369-9706330F9E0AQ27851975-6AAE1E25-D00B-4252-9CE0-3BDACE27BD32Q28473677-4875ECE3-D172-4D9F-A864-B65A8ED0FAA2Q28729012-CDF5757E-14AF-4BDF-8ECD-E4F4ADA37D0CQ30399006-D9B0EC83-1006-42AA-B92C-E612D4AAF9C9Q30469815-60A08B77-60D7-4171-AA27-33382B783DA9Q30471456-A20BA3F6-7BDA-46A7-9ABB-C2F025144691Q30486408-37704EE8-287C-4251-BD22-7145BB8FFB38Q30486628-23C6FAEE-3DAA-4BD9-85A6-27F195143514Q30542073-BA68B742-4ECB-410B-A82B-D7C9D1429354Q31123431-87F7432D-8BE0-4818-A263-6863A02E77DAQ33257718-7A365274-166F-419B-8BD6-03FCA96CA5CAQ33311571-40339897-53FE-4289-A7DD-D9A8C3AAC645Q33352155-C76C58F8-044B-425D-92AF-CA1E101D7B75Q33424301-1622EBC8-41F6-44DF-83CB-11AF1866B675Q33658544-E411C052-C4F5-40B6-96B1-EBE192907207Q33699854-8D2D50CD-624D-4D62-AFC2-735EA291EB8FQ33727047-B9B70CB3-278D-44BF-8374-AD313AAC80EBQ33733303-EE08B501-032A-4DD6-8F1B-C2889193D532Q33759627-3D88C16E-EA4F-4FE2-9718-D9FF3DFA71EFQ33760569-587B3BCE-E31F-4AD6-984C-08C23BC9D0D2Q33811126-DBC38471-75D2-4CD5-B10F-80BBFDF149F5Q33811205-1DD45732-35F5-4FF0-A844-D5838E9355F3Q33831958-964A7D72-BFF6-4F81-A7A0-4126B794A59DQ33915825-316C466A-17AF-49AD-9DC1-FD0A27ED4BEAQ33942378-E8DA1E5B-9BC3-43E1-8BEE-345AAEED515AQ34035460-78DDD4DA-6D5C-4322-A594-F0C96D3D2527Q34054213-6C14CDD1-569B-4442-A403-B6A7C365552CQ34128805-969B4421-62FF-4221-AE0F-8711E3934ECBQ34259986-D35773FE-EE0C-484D-9AE5-861F567E0497Q34272044-F1B30D8B-F0FD-4C47-8EFB-C456E85E6934Q34300091-980F5A91-658D-4D15-A841-BB5F320A998AQ34314042-063FD60E-866E-4ACE-ACD0-930A632EE8D8Q34355748-6A7D783B-26A3-41C5-B064-6E350F14B2C2Q34363400-DC3842F4-82BE-4C5F-9846-C0A2A7236CFC
P2860
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
@en
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
@nl
type
label
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
@en
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
@nl
prefLabel
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
@en
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
@nl
P2093
P356
P1433
P1476
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
@en
P2093
Dai Fukumura
Emmanuelle di Tomaso
Rakesh K Jain
Yotaro Izumi
P2888
P304
P356
10.1038/416279B
P407
P577
2002-03-01T00:00:00Z
P6179
1035406433